newsfilter
← Latest News
GlobeNewswire·

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

  • Reviva Pharmaceuticals filed a U.S. composition of matter patent application for a new brilaroxazine form to extend commercial exclusivity through 2046.
  • FDA feedback regarding the new brilaroxazine formulation for the RECOVER-2 trial & NDA is expected in Q4 2026.
  • A bioequivalence study to confirm the new formulation's comparability is scheduled to initiate in Q4 2026.
  • Patient enrollment for the RECOVER-2 Phase 3 trial is expected to begin in 1H 2027, contingent on additional financing.
  • The company reported a Q2 2026 net loss of $2.4 million ($0.19 per share), a reduction from the $6.1 million loss in Q2 2025.
  • Cash and cash equivalents totaled approximately $19.9 million as of June 30, 2026, up from $14.4 million at the end of 2025.
  • A first publication on clinical vocal biomarker data from the RECOVER Phase 3 trial was published in Biological Psychiatry.
  • Additional publications on brilaroxazine for schizophrenia treatment are anticipated in Q4 2026.
  • Reviva is actively pursuing partnership opportunities for its pipeline development.